Amgen (AMGN) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock. Over ...

Amgen’s stock has grown steadily this year ... Analysts are quite positive about the biotech company with a “Moderate Buy” ...

Taking full advantage of the stock market ... Price/Sales, and Price/Cash Flow to highlight the most attractive and discounted stocks. Thousand Oaks, CA-based Amgen is one of the biggest biotech ...

Cathie Wood’s ARK Invest is taking advantage of the recent dip in Tesla (TSLA) stock by purchasing 9,351 shares through its ...

Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating ...

MariTide’s opportunity in diabetes should not be ignored. In addition to reducing weight by 17%, it reduced HbA1c up to 2.2% ...

Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch ...

Piper Sandler analyst David Amsellem reiterated a Buy rating on Amgen (AMGN – Research Report) today and set a price target of $329.00. The ...

I believe that after Mr. Market's overreaction to the clinical data on MariTide, Amgen's stock price will continue to recover. In addition, the results showed that it has the potential to compete ...

Because of this, empirical studies indicate a strong correlation between trends in earnings estimate revisions and short-term stock price movements. Amgen is expected to post earnings of $4.18 per ...